Want to join the conversation?
For 3Q16, $CAG expects EPS to be modestly higher than comparable year-ago amounts. $CAG currently estimates proceeds from the sale of the private label operations to be about $2.7Bil, expected to be used mainly for debt reduction. $CAG also expects to generate $300MM of annual efficiency improvements by the end of FY19.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.